Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DALLAS, DEC. 05, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON DECEMBER 3, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED TWO NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 212,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

TAYSHA GENE THERAPIES ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

TSHA-102 GRANTED BREAKTHROUGH THERAPY DESIGNATION BY FDA FINALIZED FDA ALIGNMENT ON REVEAL PIVOTAL TRIAL PROTOCOL AND SAP, INCLUDING 6-MONTH INTERIM ANALYSIS THAT MAY EXPEDITE BLA SUBMISSION, WHICH WAS ENABLED BY THE RIGOROUS DEVELOPMENTAL MILESTONE EVALUATION IN PART A REVEAL PHASE 1/2 TRIALS SHOWING AN UNPRECEDENTED RESPONSE RATE DOSING OF FIRST PATIENT IN REVEAL PIVOTAL TRIAL SCHEDULED FOR Q4 2025, WITH ENROLLMENT OF ADDITIONAL PATIENTS EXPECTED TO CONTINUE AT MULTIPLE SITES THIS QUARTER PRESENTED NEW SUPPLEMENTAL ANALYSIS OF PART A REVEAL DATA REINFORCING THE BROAD AND CONSISTENT, MULTI-DOMAIN IMPACT OF TSHA-102 ON ACTIVITIES OF DAILY LIVING AT THE CNS ANNUAL MEETING TSHA-102 CONTINUES TO BE GENERALLY WELL TOLERATED WITH NO TREATMENT-RELATED SAES OR DLTS IN THE 12 PATIENTS TREATED IN THE PART A REVEAL PHASE 1/2 TRIALS AS OF OCTOBER 2025DATA CUTOFF REGAINED FULL UNENCUMBERED RIGHTS TO TSHA-102 RETT SYNDROME PROGRAM, ENABLING TAYSHA TO FOCUS ON DRIVING LONG-TERM VALUE WITH FULL STRATEGIC FLEXIBILITY AND OPTIONALITY CONFERENCE CALL AND WEBCAST TODAY AT8:30 AM EASTERN TIME DALLAS, NOV. 04, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDEDSEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE. THE PROGRESS WE'VE MADE IN THE THIRD QUARTER OF 2025 SETS THE STAGE FOR A POTENTIALLY TRANSFORMATIVE PERIOD AHEAD FOR TAYSHA.

TAYSHA GENE THERAPIES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

DALLAS, OCT. 28, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND HOST A CORPORATE UPDATE CONFERENCE CALL AND WEBCAST ON TUESDAY, NOVEMBER 4, 2025, AT 8:30 AM EASTERN TIME.

Taysha Gene Therapies, Inc.

TSHA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Taysha Gene Therapies, Inc.

TSHA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TSHA